Skip to content
Austin Top 50
Author:
ITM Isotope Technologies Munich SE
ITM to Announce Dosimetry Data from the Phase 3 COMPETE Trial at SNMMI 2026 and Host Satellite Symposium
May 19, 2026
ITM to Announce Quality of Life Data from the Phase 3 COMPETE Trial in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at ASCO 2026
April 21, 2026
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation – IRON
March 19, 2026
ITM Announces Phase 3 COMPETE Trial Post-Hoc Subgroup Analyses with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Pancreatic Neuroendocrine Tumors at ENETS 2026 Conference
March 5, 2026
←
Previous Page
1
2